Escolar Documentos
Profissional Documentos
Cultura Documentos
In parkinsonism, the dopamine content is low so that the cholinergic system is dominant.
Parkinsonism
(-)
Substantia nigra
Basal Ganglia
Parkinsons disease
(+)
PARKINSONISM
1. Bradykinesia 2. Rigidity of skeletal muscles 3. Tremors at rest 4. Postural instability 5. Sleep disorders 6. Mood changes 7. Salivation 8. Masked face
Parkinsonism is due to an imbalance between the levels of Ach & dopamine in the basal ganglia. In parkinsonism, the dopamine content is low so that the cholinergic system is dominant.
PARKINSONISM Treatment of parkinsonism 1. Anticholinergic drugs to reduce cholinergic activity or / & 2. Dopaminergic drugs to enhance dopaminergic activity: A. Directs : levodopa (L-dopa), dopaminergic
agonists B. Indirects : MAOI, Amantadine
Dopamine receptors
L-Dopa
It is the precursor of dopamine. L-Dopa
Dopa decarboxylase enzyme p
Dopamine
L-dopa
Pharmacokinetic:
Rapid absorption from small intestine Food interferes with absorption should be taken
30-60 min. before meals or (low protein diet)
L-Dopa can cross the BBB and increase the 95% of given L-Dopa is transformed to dopamine in
the peripheral tissues by decarboxylation
Blood
Brain
L-dopa dose
GIT
Metabolism in GIT
Brain
Metabolism in GIT
Peripheral tissue
(toxicity)
To:
1. Decrease the dose of L-Dopa. 2. Decrease the side effects of L-Dopa. 3. Increase the efficiency in treatment of parkinsonism.
L-dopa
Side effects: ( with carbidopa)
3. Fluctuation in response: - End of dose akinesia (wearing off reactions) - On-off phenomena 4. CVS: tachycardia, extrasystoles, postural hypotension
L-dopa
Drug interactions with L-dopa:
1. L-Dopa + Vit. B6 reduces its anti-parkinsonian effect because it elevates dopa decarboxylase activity (if used alone without carbidopa). 2. Antiemetics such as phenothiazines (Dopamine antagonists) 3. L-DOPA + MAOA inhibitors causes hypertensive crisis (due to elevated level of catecholamines). 4. Anti-cholinergic synergism drugs + L-Dopa cause
Important role in first-line therapy for Parkinsons disease In patients, who develop fluctuation in response to Ldopa or who become resistant to L-dopa
2- Selegiline
Selectively inhibits monoamine oxidase B (MAOB) which metabolizes dopamine, but doesn't inhibit MAOA (which metabolizes norepinephrine & serotonin). Thus, by decreasing the metabolism of dopamine, selegiline has been found to increase dopamine levels in the brain. It helps to decrease the dose of L-dopa & to decrease the fluctuation in response.
3.
Bromocriptine (Parlodel)
It is an ergot derivative. It is a dopamine receptor agonist. Stimulates dopaminergic receptors in the basal ganglia.
4. Amantadine
An anti-viral drug.
Decreases tremors & rigidity of parkinsonism.
It acts by:
Stimulating ganglia.
the
release
of
dopamine in the
from basal
dopaminergic
nerve
terminals
rigidity,
&